VentureMed Group Showcases FLEX Vessel Prep Advances at Symposium

VentureMed Group's Innovations in Vessel Preparation Unveiled

VentureMed Group, Inc., a leader in medical device innovations, has recently presented significant findings at a key symposium. Their FLEX Vessel Prep™ (VP) System is reshaping the landscape of arteriovenous (AV) access and peripheral arterial disease (PAD) procedures. With real-world data supporting its efficacy, this system is pivotal for maximizing patient outcomes while minimizing potential complications.

First Presentation: Insights from the FLEX FIRST AV Registry

A notable presentation led by Dr. Ari Kramer, a primary investigator from Spartanburg Medical Center, highlighted the FLEX FIRST AV Registry's 6-month findings. This multi-center observational study involved 130 hemodialysis patients dealing with AV fistula (AVF) or arteriovenous graft (AVG) complications. Dr. Kramer emphasized the system's transformative approach towards handling resistant stenoses.

"The FLEX VP System has changed the way I approach resistant stenoses. This study confirms what I've seen firsthand—controlled-depth micro-incisions offer not only technical precision but also a real clinical impact in reducing the need for repeat interventions," Dr. Kramer remarked.

The study's 6-month results showcased safe procedural practices and noteworthy durability in real-world scenarios. Key outcomes included:

• Zero serious adverse events were recorded within the one-month follow-up period.
• Overall target lesion primary patency reached 70.7% at 6 months.
• Cephalic Arch Lesion patency showed a remarkable 76.3%.
• Technical success of device delivery stood at an impressive 100% across all procedures.

Second Presentation: Enhancing Outcomes with Vessel Preparation

The subsequent presentation by Dr. Robert Shahverdyan focused on the importance of vessel preparation before drug-coated angioplasty. Dr. Shahverdyan's experience with over 70 patients revealed that using the FLEX system notably reduced reintervention rates compared to traditional methods.

"After using FLEX, the reintervention rates are markedly lower. The results are not just good; they reflect consistent performance across various access types and patient profiles," shared Dr. Shahverdyan.

The findings established the efficacy of vessel preparation before drug-coated balloon (DCB) procedures. Here are some of the critical results observed:

• Vessel Prep combined with DCB showed target lesion primary patency rates of 86.0% at 6 months and 73.6% at 12 months.
• Reinterventions per patient-year were significantly lower in the VP group (0.372) compared to traditional methods.
• In specific interventions, a staggering 75% of patients maintained their patency at 12 months with the VP approach.
• The results indicate that VP + DCB is a promising alternative for managing vascular access stenoses.

The Importance of FLEX in AV Access

Denis Harrington, President & CEO of VentureMed Group, expressed gratitude to the researchers involved: "We appreciate Dr. Kramer and Dr. Shahverdyan for their extensive research efforts. This data solidifies the foundation of evidence supporting the FLEX Vessel Prep device. Patients all over the globe deserve access to these advanced technologies and methodologies."

About VentureMed Group and the FLEX Vessel Prep™ System

VentureMed Group is dedicated to advancing endovascular solutions specifically designed for arteriovenous (AV) access and peripheral arterial disease (PAD) interventions. The FLEX Vessel Prep™ System employs the innovative Kinetic Endovascular Micro-incision Creation (KEMIC) technology, which stands apart from traditional balloon approaches. KEMIC's unique mechanism offers dynamic vessel apposition to produce precise micro-incisions, enhancing outcomes and reducing the risks associated with traditional methods.

This approach not only promotes luminal gain but also significantly improves drug absorption when combined with therapies, further lowering the risk of restenosis. FLEX is now FDA 510(k) cleared and CE Mark approved, indicating its readiness to redefine vessel preparation methodologies and improve treatment options for patients globally.

Frequently Asked Questions

What is the FLEX Vessel Prep™ System?

The FLEX Vessel Prep™ System is an advanced medical device designed to optimize vessel preparation using innovative micro-incision technology.

Who conducted the presentations on the FLEX Vessel Prep system?

The presentations were led by Dr. Ari Kramer and Dr. Robert Shahverdyan, both experts in vascular access and medical devices.

What were the key findings from the FLEX FIRST AV Registry?

The study indicated high rates of procedural safety with zero serious adverse events and a primary patency rate of 70.7% at 6 months.

What advantages does FLEX offer over traditional methods?

FLEX's controlled-depth micro-incisions lead to better clinical outcomes and reduced reinterventions compared to traditional balloon methods.

How has VentureMed Group contributed to vascular access treatments?

VentureMed Group has pioneered innovative technologies that enhance vascular access management and improve patient outcomes across different scenarios.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.